Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy

Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC…

Predictive biomarker for liver cancer associated with survival outcomes, effectiveness of systemic therapy

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Thursday 19 November →